<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by Broadridge Transform (tm) - http://www.broadridge.com -->
<!-- Created: Fri May 15 11:45:31 UTC 2026 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" targetNamespace="http://galectintherapeutics.com/20260331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:galt="http://galectintherapeutics.com/20260331" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20260331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20260331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20260331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20260331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedBalanceSheet" id="galt_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals" id="galt_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedIncomeStatement" id="galt_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedCashFlow" id="galt_r_ConsolidatedCashFlow">
        <link:definition>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ShareholdersEquityType2or3" id="galt_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/BasisofPresentationandLiquidity" id="galt_r_BasisofPresentationandLiquidity">
        <link:definition>006 - Disclosure - Basis of Presentation and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccruedExpensesandOther" id="galt_r_AccruedExpensesandOther">
        <link:definition>007 - Disclosure - Accrued Expenses and Other</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty" id="galt_r_ConvertibleNotesPayableRelatedParty">
        <link:definition>008 - Disclosure - Convertible Notes Payable &#8211; Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueofFinancialInstruments" id="galt_r_FairValueofFinancialInstruments">
        <link:definition>009 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockBasedCompensation" id="galt_r_StockBasedCompensation">
        <link:definition>010 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommonStockWarrants" id="galt_r_CommonStockWarrants">
        <link:definition>011 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LossPerShare" id="galt_r_LossPerShare">
        <link:definition>012 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommonStock" id="galt_r_CommonStock">
        <link:definition>013 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleLineofCreditRelatedPartyandSupplementalConvertibleLinesofCreditRelatedParty" id="galt_r_ConvertibleLineofCreditRelatedPartyandSupplementalConvertibleLinesofCreditRelatedParty">
        <link:definition>014 - Disclosure - Convertible Line of Credit - Related Party and Supplemental Convertible Lines of Credit - Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/Segments" id="galt_r_Segments">
        <link:definition>015 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommitmentsandContingencies" id="galt_r_CommitmentsandContingencies">
        <link:definition>016 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/Leases" id="galt_r_Leases">
        <link:definition>017 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/GalectinSciencesLLC" id="galt_r_GalectinSciencesLLC">
        <link:definition>018 - Disclosure - Galectin Sciences LLC</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccruedExpensesandOtherTables" id="galt_r_AccruedExpensesandOtherTables">
        <link:definition>996000 - Disclosure - Accrued Expenses and Other (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueofFinancialInstrumentsTables" id="galt_r_FairValueofFinancialInstrumentsTables">
        <link:definition>996001 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockBasedCompensationTables" id="galt_r_StockBasedCompensationTables">
        <link:definition>996002 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommonStockWarrantsTables" id="galt_r_CommonStockWarrantsTables">
        <link:definition>996003 - Disclosure - Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LossPerShareTables" id="galt_r_LossPerShareTables">
        <link:definition>996004 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SegmentsTables" id="galt_r_SegmentsTables">
        <link:definition>996005 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/BasisofPresentationandLiquidityDetails" id="galt_r_BasisofPresentationandLiquidityDetails">
        <link:definition>996006 - Disclosure - Basis of Presentation and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccruedExpensesTable" id="galt_r_AccruedExpensesTable">
        <link:definition>996007 - Disclosure - Accrued Expenses and Other - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails" id="galt_r_ConvertibleNotesPayableRelatedPartyDetails">
        <link:definition>996008 - Disclosure - Convertible Notes Payable &#8211; Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueofFinancialInstrumentsDetails" id="galt_r_FairValueofFinancialInstrumentsDetails">
        <link:definition>996009 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AssetsandLiabilitiesMeasuredandRecordedatFairValueonRecurringBasisTable" id="galt_r_AssetsandLiabilitiesMeasuredandRecordedatFairValueonRecurringBasisTable">
        <link:definition>996010 - Disclosure - Fair Value of Financial Instruments - Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AprilNoteKeyAssumptionsTable" id="galt_r_AprilNoteKeyAssumptionsTable">
        <link:definition>996011 - Disclosure - Fair Value of Financial Instruments - April Note, Key Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/RollForwardofAprilNoteDerivativeLiabilityTable" id="galt_r_RollForwardofAprilNoteDerivativeLiabilityTable">
        <link:definition>996012 - Disclosure - Fair Value of Financial Instruments - Roll Forward of April Note Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SeptemberNoteKeyAssumptionsTable" id="galt_r_SeptemberNoteKeyAssumptionsTable">
        <link:definition>996013 - Disclosure - Fair Value of Financial Instruments - September Note, Key Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/RollForwardofSeptemberNoteDerivativeLiabilityTable" id="galt_r_RollForwardofSeptemberNoteDerivativeLiabilityTable">
        <link:definition>996014 - Disclosure - Fair Value of Financial Instruments - Roll Forward of September Note Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/DecemberNoteKeyAssumptionsTable" id="galt_r_DecemberNoteKeyAssumptionsTable">
        <link:definition>996015 - Disclosure - Fair Value of Financial Instruments - December Note, Key Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/RollForwardofDecemberNoteDerivativeLiabilityTable" id="galt_r_RollForwardofDecemberNoteDerivativeLiabilityTable">
        <link:definition>996016 - Disclosure - Fair Value of Financial Instruments - Roll Forward of December Note Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockBasedCompensationDetails" id="galt_r_StockBasedCompensationDetails">
        <link:definition>996017 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ComponentsofStockBasedCompensationExpenseTable" id="galt_r_ComponentsofStockBasedCompensationExpenseTable">
        <link:definition>996018 - Disclosure - Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockOptionActivityTable" id="galt_r_StockOptionActivityTable">
        <link:definition>996019 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/WeightedAverageAssumptionsUsedtoDetermineFairValueofOptionsGrantedTable" id="galt_r_WeightedAverageAssumptionsUsedtoDetermineFairValueofOptionsGrantedTable">
        <link:definition>996020 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommonStockWarrantsDetails" id="galt_r_CommonStockWarrantsDetails">
        <link:definition>996021 - Disclosure - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommonStockWarrantsTable" id="galt_r_CommonStockWarrantsTable">
        <link:definition>996022 - Disclosure - Common Stock Warrants - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LossPerShareTable" id="galt_r_LossPerShareTable">
        <link:definition>996023 - Disclosure - Loss Per Share - Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommonStockDetails" id="galt_r_CommonStockDetails">
        <link:definition>996024 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleLineofCreditRelatedPartyandSupplementalConvertibleLinesofCreditRelatedPartyDetails" id="galt_r_ConvertibleLineofCreditRelatedPartyandSupplementalConvertibleLinesofCreditRelatedPartyDetails">
        <link:definition>996025 - Disclosure - Convertible Line of Credit - Related Party and Supplemental Convertible Lines of Credit - Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SegmentsDetails" id="galt_r_SegmentsDetails">
        <link:definition>996026 - Disclosure - Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SignificantExpenseandAssetCategoriesTable" id="galt_r_SignificantExpenseandAssetCategoriesTable">
        <link:definition>996027 - Disclosure - Segments - Significant Expense and Asset Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommitmentsandContingenciesDetails" id="galt_r_CommitmentsandContingenciesDetails">
        <link:definition>996028 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LeasesDetails" id="galt_r_LeasesDetails">
        <link:definition>996029 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/GalectinSciencesLLCDetails" id="galt_r_GalectinSciencesLLCDetails">
        <link:definition>996030 - Disclosure - Galectin Sciences LLC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:element name="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent"/>
  <xs:element name="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent"/>
  <xs:element name="UndesignatedCapitalStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_UndesignatedCapitalStockValue"/>
  <xs:element name="UndesignatedCapitalStockParValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_UndesignatedCapitalStockParValue"/>
  <xs:element name="UndesignatedCapitalStockSharesAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_UndesignatedCapitalStockSharesAuthorized"/>
  <xs:element name="UndesignatedCapitalStockSharesDesignated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_UndesignatedCapitalStockSharesDesignated"/>
  <xs:element name="OperatingLeaseRightOfUseAssetAmortizationPeriodicReductionAndRecovery" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="galt_OperatingLeaseRightOfUseAssetAmortizationPeriodicReductionAndRecovery"/>
  <xs:element name="ConvertiblePreferredStockDividends" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="galt_ConvertiblePreferredStockDividends"/>
  <xs:element name="ConvertiblePreferredStockDividendsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ConvertiblePreferredStockDividendsShares"/>
  <xs:element name="TemporaryEquityDividends" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="galt_TemporaryEquityDividends"/>
  <xs:element name="TemporaryEquityDividendsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_TemporaryEquityDividendsShares"/>
  <xs:element name="StockIssuedDuringPeriodValueStockBasedCompensationExpenseNetOfSharesForfeitedToCoverTaxWithholding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_StockIssuedDuringPeriodValueStockBasedCompensationExpenseNetOfSharesForfeitedToCoverTaxWithholding"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockBasedCompensationExpenseNetOfSharesForfeitedToCoverTaxWithholding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_StockIssuedDuringPeriodSharesStockBasedCompensationExpenseNetOfSharesForfeitedToCoverTaxWithholding"/>
  <xs:element name="CommonStockWarrantsDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_CommonStockWarrantsDisclosureTextBlock"/>
  <xs:element name="AccruedResearchAndDevelopmentCostsAndOtherCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="QuarterlyInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_QuarterlyInterestRate"/>
  <xs:element name="AnnualInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_AnnualInterestRate"/>
  <xs:element name="NumberOfPromissoryNotesEvidencedByLoansAgreement" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement"/>
  <xs:element name="VestingPercentageOfRestrictedStockUnits" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_VestingPercentageOfRestrictedStockUnits"/>
  <xs:element name="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent"/>
  <xs:element name="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent"/>
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne"/>
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo"/>
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree"/>
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour"/>
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive"/>
  <xs:element name="AggregateOfferingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_AggregateOfferingPrice"/>
  <xs:element name="CommissionRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_CommissionRate"/>
  <xs:element name="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
  <xs:element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock"/>
  <xs:element name="IssuanceOfWarrantsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_IssuanceOfWarrantsValue"/>
  <xs:element name="DebtInstrumentAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_DebtInstrumentAccruedInterest"/>
  <xs:element name="ContractCancelationNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ContractCancelationNoticePeriod"/>
  <xs:element name="NumberOfOperatingLeases" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_NumberOfOperatingLeases"/>
  <xs:element name="FreeRentPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_FreeRentPeriod"/>
  <xs:element name="CapitalContributionExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_CapitalContributionExpense"/>
  <xs:element name="AdditionalSupplementalLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_AdditionalSupplementalLineOfCreditMember"/>
  <xs:element name="April2025PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_April2025PromissoryNoteMember"/>
  <xs:element name="AprilConvertiblePromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_AprilConvertiblePromissoryNoteMember"/>
  <xs:element name="BusinessOperatingSegmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_BusinessOperatingSegmentMember"/>
  <xs:element name="ContingentInterestAprilNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ContingentInterestAprilNoteMember"/>
  <xs:element name="ContingentInterestDecemberNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ContingentInterestDecemberNoteMember"/>
  <xs:element name="ContingentInterestSeptemberNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ContingentInterestSeptemberNoteMember"/>
  <xs:element name="December2022PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_December2022PromissoryNoteMember"/>
  <xs:element name="December2023PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_December2023PromissoryNoteMember"/>
  <xs:element name="December2025PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_December2025PromissoryNoteMember"/>
  <xs:element name="December2025SupplementalLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_December2025SupplementalLineOfCreditMember"/>
  <xs:element name="DecemberConvertiblePromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_DecemberConvertiblePromissoryNoteMember"/>
  <xs:element name="GalectinSciencesLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_GalectinSciencesLLCMember"/>
  <xs:element name="JulySupplementalCreditAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_JulySupplementalCreditAgreementMember"/>
  <xs:element name="June2023PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_June2023PromissoryNoteMember"/>
  <xs:element name="June2024PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_June2024PromissoryNoteMember"/>
  <xs:element name="June2025PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_June2025PromissoryNoteMember"/>
  <xs:element name="March2023PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_March2023PromissoryNoteMember"/>
  <xs:element name="March2025SupplementalCreditAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_March2025SupplementalCreditAgreementMember"/>
  <xs:element name="March24PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_March24PromissoryNoteMember"/>
  <xs:element name="SBHSciencesIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_SBHSciencesIncMember"/>
  <xs:element name="September2024PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_September2024PromissoryNoteMember"/>
  <xs:element name="SeptemberConvertiblePromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_SeptemberConvertiblePromissoryNoteMember"/>
  <xs:element name="SeriesAAndSeriesCPreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_SeriesAAndSeriesCPreferredStockMember"/>
  <xs:element name="SupplementalLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_SupplementalLineOfCreditMember"/>
  <xs:element name="TwoThousandTwentyMarketAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_TwoThousandTwentyMarketAgreementMember"/>
  <xs:element name="WarrantEightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantEightMember"/>
  <xs:element name="WarrantFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantFiveMember"/>
  <xs:element name="WarrantFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantFourMember"/>
  <xs:element name="WarrantNineMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantNineMember"/>
  <xs:element name="WarrantOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantOneMember"/>
  <xs:element name="WarrantSevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantSevenMember"/>
  <xs:element name="WarrantSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantSixMember"/>
  <xs:element name="WarrantTenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantTenMember"/>
  <xs:element name="WarrantThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantThreeMember"/>
  <xs:element name="WarrantTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantTwoMember"/>
  <xs:element name="CommonStockWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_CommonStockWarrantsAbstract"/>
<!-- [WMV7][RJaIUm2FjrQH8yGakn4oJTsxQ37cAA3d0M+P4OCdDnM7OdM1v2FKj7sZwTLkPuxFTqWIJSdiUa6u81IVYslRSjcv/jagJoO7f04gBCPpH+dZxbAh2Iu11UgJ/wpbOXEc9y3k1YRYGNiB6lSpPYx/0ccOLAxxGv8MNGGoYzA8CL8LapETsaEvwwsmMigysCCd1F/bsN2/91gFLjJ4DN2jn68S2D9KS7T3r+r3KwV2rlL4ma4jc1fxqVIyt+IYBAYU1ff39sYlDBxgZ0WgdX0atiPzfyaxhZjnKtC0RaM5WtT3RZuV9HHw1SteXyqWtDmiijADIStzjgyaTySux2TbchiHrkGiqCf66UA15ZJ2o7SZpEMdcQ==] CSR-->
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_DocumentAndEntityInformationAbstract"/>
</xs:schema>
